This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

Browse

Fluvoxamine

Extensively Studied

SSRI + sigma-1 receptor agonist | Luvox, Faverin — primary OCD indication, strongest CYP1A2 inhibitor in class, controversial early-COVID-19 repurposing

Aliases (5)
Luvox · Faverin · Floxyfral · Dumirox · fluvoxamine maleate
TYPICAL DOSE
100-300 mg/day (OCD therapeutic range; titrate …
Daily qHS (BID >150 mg)
ROUTE
Oral (immediate-release tablets, controlled-rel…
CYCLE
Continuous; 12+ weeks for OCD response evaluation
STORAGE
Room temp; original container; protect from moi…

Overview

What is Fluvoxamine?

Fluvoxamine (brand names Luvox, Faverin, Floxyfral, Dumirox) is a selective serotonin reuptake inhibitor (SSRI) FDA-approved for obsessive-compulsive disorder in adults (1994) and pediatric patients aged 8-17 (1997). Marketed for major depressive disorder outside the US. Differentiated from other SSRIs by its strong sigma-1 receptor agonism and the strongest CYP1A2 inhibition in the class — both of which drive most of its distinctive clinical and interaction profile.

Key Benefits

Robust efficacy for OCD across age groups (adult + pediatric), social anxiety, and OCD-spectrum conditions. Sigma-1 agonism gives it a theoretical pro-cognitive and neuroprotective edge vs other SSRIs, with controversial early-COVID-19 outpatient signal in the TOGETHER trial. Half-life ~15 hours, no active metabolite — predictable PK once steady-state reached.

Mechanism of Action

Inhibits the serotonin transporter (SERT) raising synaptic serotonin — standard SSRI mechanism. Distinguishes itself by (1) high-affinity sigma-1 receptor agonism (Ki ~36 nM, highest in class) modulating ER-stress, NMDA tone, BDNF, and neurosteroid signalling; and (2) potent CYP1A2 inhibition plus moderate CYP2C19 inhibition — driving extensive drug interactions with caffeine, melatonin, ramelteon, theophylline, agomelatine, clopidogrel, PPIs, warfarin, clozapine, olanzapine, duloxetine, and tizanidine.

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

CYP1A2: strongest inhibitor among SSRIs

substrate examples: caffeine, melatonin, ramelteon, theophylline, agomelatine, tizanidine, mexiletine, clozapine, olanzapine, duloxetine,…

Effective

CYP2C19: moderate-strong inhibitor

substrate examples: clopidogrel (active metabolite formation blocked), PPIs, S-warfarin, citalopram/escitalopram, diazepam.

Peptide Interactions

MAOIs
Avoid

(phenelzine, tranylcypromine, selegiline, linezolid, methylene blue): serotonin syndrome — absolute contraindication, 14-day washout.

Other serotonergics:
Avoid

tramadol, 5-HTP, MDMA, St John's wort, dextromethorphan (high dose), other SSRIs/SNRIs.

CYP1A2 substrates:
Avoid

caffeine (effectively contraindicated at any meaningful intake), melatonin (~17× AUC), ramelteon (~190× AUC, FDA contraindication), agomelatine (~60× AUC, EU…

CYP2C19 substrates:
Avoid

clopidogrel (reduced antiplatelet effect — relevant post-stent), PPIs (modest exposure increase), warfarin (INR rise).

QT-prolonging combinations
Avoid

at high cumulative load.

CBT / Exposure and Response Prevention (ERP):
Synergistic

First-line behavioral therapy for OCD; combination outperforms either alone.

Low-dose atypical antipsychotic augmentation
Synergistic

(risperidone, aripiprazole) for OCD-resistant cases.

Quality Indicators

Pharmacy-dispensed, intact packaging

Prescription tablets in original sealed blister/bottle from a licensed pharmacy. Generic fluvoxamine maleate is FDA AB-rated and fully bioequivalent.

!

IR vs CR formulation

Immediate-release and controlled-release fluvoxamine are not interchangeable mg-for-mg. CR avoids BID dosing above 150 mg/day but is more expensive. Confirm formulation when switching.

!

Generic switching across countries

Fluvoxamine is widely generic (Faverin, Floxyfral, Dumirox, Luvox). International generics can have differing excipients; track if symptoms shift after switching brand.

Unbranded blister or counterfeit risk

Avoid international online pharmacies of unknown provenance. Counterfeit psychiatric medications are a documented issue; verify pharmacy and lot number.

What to Expect

  • Day 1-7
    Sedation prominent (qHS dosing helps), nausea, headache. Often a "thicker" feeling than sertraline — partly sigma-1, partly histamine cross-talk debate.
  • Week 2-4
    Caffeine sensitivity becomes obvious — most users have to drop caffeine entirely. Initial OCD/anxiety response begins.
  • Week 4-12
    Class-typical SSRI emotional blunting; sexual dysfunction (anorgasmia, low libido) often emerges and persists. Y-BOCS responders see meaningful symptom drop.

Side Effects & Safety

  • Common (>10%): Nausea (especially first weeks), somnolence, headache, insomnia (paradoxical), dry mouth, dizziness, asthenia, sexual dysfunction (30-60%).
  • Less common (1-10%): Sweating, anorexia/weight changes (variable), tremor, palpitations, anorgasmia, ejaculation delay.
  • Rare-serious (<1%): Serotonin syndrome, hyponatremia (especially elderly), suicidal ideation <25 yr (FDA black box, class-wide), hepatotoxicity (rare), bleeding (platelet 5-HT depletion), QT prolongation (lower risk than citalopram).
  • Specific watch periods: First 4 weeks for activation/suicidality; long-term for sexual side effects and weight; LFTs if hepatic risk factors present.

References

PMID 29477251

pubmed.ncbi.nlm.nih.gov · 2018

Cipriani et al. 2018, comparative efficacy of 21 antidepressants (Lancet).

View Study

PMID 34717820

pubmed.ncbi.nlm.nih.gov · 2022

Reis et al. 2022, TOGETHER trial fluvoxamine COVID-19 (Lancet Glob Health).

View Study

PMID 20021348

pubmed.ncbi.nlm.nih.gov · 2009

Hashimoto 2009, sigma-1 SSRI review (Cent Nerv Syst Agents Med Chem).

View Study

PMID 12814817

pubmed.ncbi.nlm.nih.gov · 2003

Greenberg et al. 2003, SSRIs in OCD (Psychiatr Clin North Am).

View Study

PMID 11106136

pubmed.ncbi.nlm.nih.gov · 2000

Härtter et al. 2000, fluvoxamine + melatonin AUC (J Clin Psychopharmacol).

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources